<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283578</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/15/7825</org_study_id>
    <nct_id>NCT04283578</nct_id>
  </id_info>
  <brief_title>Oxytocin Treatment in Neonates and Infants With Prader-Willi Syndrome</brief_title>
  <acronym>OTBB3</acronym>
  <official_title>Oxytocin Treatment in Neonates and Infants Aged From 0 to 3 Months With Prader-Willi Syndrome : a Study of Safety and Efficacy on Oral and Social Skills and Feeding Behavior of Intranasal Administration of Oxytocin vs Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Clinical Trials Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Epidemiological and Clinical Research Information Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, placebo-controlled, double-blind part of the phase III trial to
      assess the safety and efficacy of 4 weeks oxytocin (OT) administration on oral and social
      skills in neonates/infants with Prader-Willi Syndrome (PWS) aged less than 3 months at
      inclusion. Phase III clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neonatal Oral-Motor Assessment Scale (NOMAS) scale</measure>
    <time_frame>4 weeks</time_frame>
    <description>the score goes from 8 to 28, the higher the score meaning a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ghrelin dosage</measure>
    <time_frame>Day 0, Week 1 and week 4</time_frame>
    <description>Concentration of ghrelin (unacylated/UAG and acylated/AG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxytocin dosage</measure>
    <time_frame>Day 0, week 4</time_frame>
    <description>Plasma Oxytocin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proficiency score</measure>
    <time_frame>Day 0, Week and week 4</time_frame>
    <description>The volume of milk taken in the first five minutes of feeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal administration of OT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intranasal administration of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OT</intervention_name>
    <description>One group will receive OT for 4 weeks, then placebo or OT for 8 weeks</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>oxytocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>One group will receive Placebo for 4 weeks, then Placebo or OT for 8 weeks.</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female neonate or infant, with PWS genetically confirmed.

          2. Age &lt;92 days (plus a tolerance of up to 8 days maximum) (for preterm infants, born
             before 37 weeks amenorrhea, corrected age will be applied).

          3. Signed informed consent obtained from the parents/holders of parental authority.

          4. Parents willing and able to comply with all study procedures.

        Exclusion Criteria:

          -  1. Neonate or infant currently admitted to the emergency care unit for ongoing
             life-threatening comorbidities like severe respiratory, cardiovascular or neurological
             abnormalities.

             2. Neonate or infant with prolongation of the QT interval. 3. Neonate or infant
             without medical insurance. 4. Neonate or infant with hypersensitivity to oxytocin or
             excipients of the product.

             5. Neonate or infant with concomitant treatment prolonging QT interval 6. Neonate or
             infant with family history of genetic pathology causing QT interval prolongation.

             7. Neonate or infant with hypokalemia (clinically relevant at the discretion of the
             doctor).

             8. Neonate or infant participating simultaneously in another interventional study.

             9. Neonates or infants whose parents' situations may jeopardize the interpretation of
             the results.

             10. Neonates or infants whose parents' refuse video recording, required to respond to
             the primary objective of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>92 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maithé TAUBER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maithé TAUBER, MD</last_name>
    <phone>33-561778771</phone>
    <email>tauber.m@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadège ALGANS</last_name>
    <phone>33-561778771</phone>
    <email>algans.n@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maithe TAUBER</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>April 5, 2020</last_update_submitted>
  <last_update_submitted_qc>April 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

